Merck just slashed its full-year profit forecast — from $5.04 to $5.16 per share to a range of $2.66 to $2.76 — due to hefty one-time charges from recent acquisitions, including $2.31 for Terns Pharma and $3.62 from Cidara Therapeutics. Despite the earnings hit, Merck raised its revenue outlook to $66.3B–$67.3B, up from prior estimates, after Q2 revenue hit $16.61B — beating expectations. Though Q2 ended with a net loss thanks to those charges, adjusted results outperformed forecasts. Keytruda and Keytruda Qlex drove over $8.3B in sales, while Winrevair surged 75% and Capvaxive rose 42%. Animal health also thrived, and a new cholesterol drug just got FDA approval.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
